Objective: The purpose of this study was to evaluate the prevalence of Chlamydia trachomatis in our rural obstetric population and assess the appropriateness of selective vs. universal prenatal screening. 
hlamydia trachomatis is the most common bacterial sexually transmitted disease (STD) in the United States. Many reports have described serious complications that may result from C. trachomatis infection during pregnancy. C. trachomatis has been implicated in premature rupture of membranes and premature labor and associated with low birth weight, stillbirth, and neonatal death. [1] [2] [3] [4] In the postpartum period, C. trachomatis has been identified as a cause of late postpartum endometritis, s It is important to note, however, that not all studies of C. trachomatis in pregnancy have supported the association of C. trachomatis with any or all of these complications. Some have found no linkage, while others found an association only in the subset of C.
trachomatis-infected patients who are also positive for C. trachomatis IgM antibodies.
6-1 Less controversial is the neonatal infectious morbidity associated with maternal C. trachomatis infection. Of neonates born to mothers with untreated C. trachomatis, it is estimated that 30% will develop C. trachomat# ophthalmia neonatorum and 35% will' develop Chlamydia pneumonia. 12 Although these are usually benign and easily treated illnesses, approximately 25% of infants with pneumonia require hospitalization and one report has described permanent respiratory sequelae in infants with pneumonia. 13--14 The fact that C. trachomatis screening of pregnant patients and treatment of those infected can eliminate most or all of the complications described above has led to the recommendation for expanded determining the need to screen for C. trachomatis, the process becomes more straightforward and provideo" compliance will likely improve. We have also subjected the 3 risk factors utilized for this study to logistic regression analysis which documented the importance of each of the 3 risk (actors. Finally, we wish to emphasize that this risk factor assessment should not preclude the use of a provider's clinical judgment regarding C. trachomatis screening in individual patients.
Another concern about C. trachomatis screening is the particular screening test being used. Cell culture remains the "gold standard" but is more costly and associated with greater transport difficulties than are non-culture techniques. Therefore, these non-culture assays have become the most common methods of C. trachomat# screening. Although they have excellent sensitivity and specificity, their specificity is still less than that of cell culture. 
